There is a good article in the latest issue of Pharmaceutical Technology Europe which explores the ever present debate around the use of human embryonic stem cells in medical research and the legal boundaries in different parts of the world. Whilst there are certainly many medical benefits that can arise from further research in these areas, there is still no general consensus on how such research should be funded or indeed commercialised following any successful findings.
